HK Stock Market Move | ASCLETIS-B (01672) rises nearly 9% intraday; once-weekly oral peptide pipeline for obesity treatment achieves positive preclinical data.

ASCLETIS-B (01672) rose nearly 9% intraday. As of press time, it was up 5.58% at HK$6.05, with turnover of HK$9.8298 million. On the news front, Ascletis Pharma announced that its most comprehensive once-weekly oral peptide pipeline for the treatment of obesity has achieved positive preclinical data. The pipeline covers all four validated targets, including multiple first-in-class fixed-dose combination formulations. The announcement noted that the oral amylin receptor agonist peptide ASC36o is the most advanced candidate in the pipeline and is currently in a Phase I study in the United States. ASC36o demonstrated a half-life of approximately 7 days and oral bioavailability of 6% to 8% in non-human primates, supporting once-weekly oral dosing.